Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
Phase 1
Completed
- Conditions
- MetastasisLocally Advanced Solid TumorRecurrent Cancer
- Interventions
- Radiation: Palliative radiotherapy
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- XRad Therapeutics Inc
- Target Recruit Count
- 12
- Registration Number
- NCT05002140
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Stanford Clinical Cancer Center, Stanford, California, United States
© Copyright 2025. All Rights Reserved by MedPath